Here is the design of a clinical trial:

Official Title: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. a Randomised Phase III Trial

Included conditions:
- Non-small Cell Lung Cancer

Study Armgroups:
- {'label': 'Systemic Anti-Cancer Therapy (SACT) alone', 'type': 'ACTIVE_COMPARATOR', 'description': 'The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.', 'interventionNames': ['Other: Non-investigational SACT']}
- {'label': 'SACT + Radical Radiotherapy (Conventional RT and SABR)', 'type': 'EXPERIMENTAL', 'description': 'SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.\n\nThe choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.', 'interventionNames': ['Radiation: Radical Radiotherapy (Conventional RT and SABR)']}

Interventions:
- {'type': 'RADIATION', 'name': 'Radical Radiotherapy (Conventional RT and SABR)', 'description': 'Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases', 'armGroupLabels': ['SACT + Radical Radiotherapy (Conventional RT and SABR)']}
- {'type': 'OTHER', 'name': 'Non-investigational SACT', 'description': 'There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.', 'armGroupLabels': ['Systemic Anti-Cancer Therapy (SACT) alone']}

Primary Outcomes:
- {'measure': 'Overall Survival', 'description': 'The trial will investigate the impact of the addition of radical conventional and stereotactic radiotherapy to standard systemic therapy on overall survival', 'timeFrame': 'From date of randomisation to the date of death, up to 36 months'}

Please estimate the sample size based on the assumption: 
Two-sided 5% alpha, 85% power, 10% dropout rate
Sample size and study duration
        In total, 340 patients are required (170 per arm) to detect an improvement in median survival from 9.9 to 14.3 months, that is, a HR of at least 0.69, with a two-sided 5% alpha and 85% power and a 10% dropout rate.
        Prior to study initiation, a survey was sent to all UK radiotherapy centres on their SABR/SRS practices. At least 26 centres replied with an average of 4.6 suitable study patients in the previous 6 months. Assuming only half of this amount would satisfy the eligibility criteria, this would equate to around 120 patients. We thus expect that the trial will take around 3 years to accrue. We hope to include more than 30 centres in our study in improve on trial participation. Nevertheless, an early feasibility study will be conducted after the first 50 patients. The study opened August 2016.